Hospital
Carilion New River Valley Medical Center
Carilion New River Valley Medical Center was paid $32.42M by Medicaid between Jan 2018 and Dec 2024, across 287 billing codes. Its largest line is 99283, emergency room visit (moderate) — 10% of everything it billed.
33Billing provider infoCARILION NEW RIVER VALLEY MEDICAL CENTER
CHRISTIANSBURG, VA 24073
CHRISTIANSBURG, VA 24073
33aNPI1376536573assigned 08/24/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$32.42M
24GClaims812,349
24DCodes billed287
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#24 of 80
Median peer was paid$14.69M
This provider vs. median2.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GRISETTI, NICOLE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 75,565 | $2.00M | |
| 2019 | 122,062 | $3.80M | |
| 2020 | 105,078 | $3.84M | |
| 2021 | 133,780 | $4.80M | |
| 2022 | 133,275 | $5.55M | |
| 2023 | 134,944 | $6.40M | |
| 2024incomplete | 107,645 | $6.03M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 10% | 19,829 | 17,688 | $3.39M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 19,814 | 17,145 | $3.28M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.4% | 13,772 | 11,953 | $2.39M |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.3% | 7,836 | 6,653 | $2.36M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.6% | 39,146 | 11,609 | $2.13M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 5.0% | 4,953 | 4,554 | $1.63M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.9% | 6,544 | 5,904 | $1.28M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.7% | 2,196 | 1,972 | $862K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 5,449 | 4,959 | $856K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 4,965 | 4,373 | $816K |
| 78451 | 2.2% | 1,542 | 1,397 | $723K | |
| 97161 | 2.0% | 4,745 | 4,464 | $647K |
275 more codes
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 2.0% | 1,088 | $637K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.8% | 4,176 | $588K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.6% | 7,767 | $533K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.5% | 1,763 | $483K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.4% | 1,386 | $465K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 1.3% | 4,200 | $428K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.1% | 1,802 | $363K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 1,817 | $359K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 1,882 | $346K |
| 59025 | Fetal non-stress test | 1.0% | 1,640 | $336K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 5,932 | $307K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,054 | $294K |
| 76830 | Ultrasound, transvaginal | <1% | 2,629 | $292K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,531 | $273K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,428 | $266K |
| 99220 | <1% | 4,544 | $255K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 707 | $248K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,356 | $230K |
| 93017 | <1% | 2,651 | $230K | |
| 95806 | <1% | 435 | $214K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,299 | $184K |
| 97162 | <1% | 1,756 | $183K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 97 | $164K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 173 | $162K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 249 | $157K |
| 93971 | <1% | 1,511 | $146K | |
| 94060 | <1% | 2,276 | $145K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,448 | $144K |
| 80053 | Comprehensive metabolic panel | <1% | 30,948 | $138K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,078 | $135K |
| 72141 | <1% | 720 | $135K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,358 | $127K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 875 | $126K |
| 76642 | <1% | 1,065 | $117K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 489 | $111K |
| 93880 | <1% | 1,088 | $97K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 451 | $95K |
| 76536 | <1% | 810 | $95K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,896 | $94K |
| 70496 | <1% | 383 | $87K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 897 | $87K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 23,414 | $86K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,364 | $84K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,090 | $84K |
| 59899 | <1% | 118 | $78K | |
| 94726 | <1% | 2,303 | $76K | |
| 93970 | <1% | 542 | $75K | |
| 74183 | <1% | 272 | $74K | |
| 94729 | <1% | 2,366 | $68K | |
| 71250 | <1% | 996 | $67K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 546 | $65K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,712 | $55K |
| 97163 | <1% | 359 | $49K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,878 | $47K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,851 | $47K |
| 47562 | <1% | 12 | $44K | |
| 74018 | <1% | 2,284 | $43K | |
| 99234 | <1% | 1,913 | $40K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 3,568 | $40K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,351 | $38K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 44 | $37K |
| 97166 | <1% | 295 | $34K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,800 | $34K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,847 | $32K |
| 76770 | <1% | 215 | $29K | |
| 95816 | <1% | 86 | $29K | |
| 99235 | <1% | 1,247 | $26K | |
| 93225 | <1% | 816 | $26K | |
| 83880 | <1% | 3,094 | $26K | |
| 77065 | Tomosynthesis, mammo | <1% | 570 | $24K |
| 70498 | <1% | 552 | $23K | |
| 95811 | <1% | 49 | $23K | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 2,773 | $21K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 39,673 | $21K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,310 | $20K |
| 71045 | Radiologic examination, chest; single view | <1% | 9,048 | $20K |
| 96415 | <1% | 59 | $19K | |
| 73630 | <1% | 1,736 | $19K | |
| 77066 | Tomosynthesis, mammo | <1% | 401 | $18K |
| 84484 | <1% | 13,657 | $18K | |
| 74420 | <1% | 112 | $18K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 14 | $15K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 49 | $15K |
| 73030 | <1% | 1,290 | $15K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,192 | $14K |
| 73564 | <1% | 1,561 | $13K | |
| 72110 | <1% | 760 | $13K | |
| 73610 | <1% | 1,268 | $12K | |
| J3490 | Unclassified drugs | <1% | 43,740 | $12K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,141 | $11K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,417 | $11K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 162 | $11K |
| 93922 | <1% | 149 | $11K | |
| 82565 | <1% | 3,569 | $11K | |
| 73221 | <1% | 44 | $11K | |
| 49083 | <1% | 21 | $10K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,643 | $10K |
| 71271 | <1% | 97 | $10K | |
| G0378 | Hospital observation service, per hour | <1% | 512 | $10K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 490 | $9K |
| 73130 | <1% | 1,059 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,167 | $9K |
| 93458 | <1% | 12 | $9K | |
| 72100 | <1% | 260 | $9K | |
| 90715 | <1% | 430 | $8K | |
| 78227 | <1% | 25 | $8K | |
| 93270 | <1% | 221 | $8K | |
| 87040 | <1% | 1,206 | $8K | |
| 85379 | <1% | 1,765 | $7K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,920 | $7K |
| 85610 | <1% | 5,415 | $7K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 21 | $7K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 33 | $7K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 71 | $7K |
| 73502 | <1% | 608 | $7K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 15,627 | $6K |
| 74174 | <1% | 30 | $6K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 234 | $6K |
| 72131 | <1% | 99 | $6K | |
| 97165 | <1% | 52 | $6K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 14 | $5K |
| 83605 | <1% | 3,848 | $5K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 352 | $5K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,486 | $5K |
| 86850 | <1% | 2,739 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,832 | $5K |
| 86900 | <1% | 2,946 | $5K | |
| 73110 | <1% | 613 | $4K | |
| 80179 | <1% | 907 | $4K | |
| 93226 | <1% | 125 | $4K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 53 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,065 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,252 | $4K |
| 76870 | <1% | 45 | $4K | |
| 70486 | <1% | 69 | $4K | |
| 97802 | <1% | 52 | $4K | |
| 82962 | <1% | 8,937 | $3K | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,108 | $3K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 13 | $3K |
| 84703 | <1% | 7,221 | $3K | |
| 80047 | <1% | 1,113 | $3K | |
| 12001 | <1% | 19 | $3K | |
| 81001 | <1% | 12,577 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,177 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 857 | $2K |
| 86901 | <1% | 2,965 | $2K | |
| 88342 | <1% | 775 | $2K | |
| 85027 | <1% | 2,331 | $2K | |
| 83735 | <1% | 6,213 | $2K | |
| 83690 | <1% | 7,698 | $2K | |
| 80143 | <1% | 954 | $2K | |
| 85730 | <1% | 2,442 | $2K | |
| J2805 | Injection, sincalide, 5 micrograms | <1% | 13 | $2K |
| 77085 | <1% | 28 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,697 | $1K |
| 87186 | <1% | 1,728 | $1K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 36,491 | $1K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,842 | $1K |
| 81003 | <1% | 4,464 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 14,852 | $1K |
| C9399 | Unclassified drugs or biologicals | <1% | 101 | $1K |
| 97116 | <1% | 22 | $1K | |
| 72072 | <1% | 70 | $1K | |
| 82803 | <1% | 854 | $1K | |
| 87075 | <1% | 99 | $1K | |
| 86140 | <1% | 2,311 | $980.57 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 44 | $977.40 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,738 | $972.37 |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 27 | $911.14 |
| 88304 | <1% | 158 | $886.08 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,660 | $871.44 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,975 | $764.87 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,504 | $674.51 |
| 85014 | <1% | 1,732 | $671.17 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 8,861 | $666.25 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 651 | $633.50 |
| 73590 | <1% | 85 | $571.79 | |
| 81025 | <1% | 1,972 | $534.75 | |
| 36416 | <1% | 557 | $514.22 | |
| 96376 | <1% | 4,717 | $496.66 | |
| 73080 | <1% | 75 | $484.74 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 164 | $470.03 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,285 | $462.53 |
| 87081 | <1% | 1,860 | $461.05 | |
| 99152 | <1% | 806 | $451.09 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 14 | $437.35 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,134 | $426.94 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,403 | $421.85 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,862 | $403.83 |
| 84702 | <1% | 1,010 | $358.52 | |
| 87077 | <1% | 1,126 | $352.49 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,427 | $330.91 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,937 | $282.66 |
| 99153 | Mod sedat endo service >5yrs | <1% | 210 | $277.93 |
| 94010 | <1% | 14 | $270.33 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,120 | $267.11 |
| 73090 | <1% | 33 | $247.23 | |
| 80061 | Lipid panel | <1% | 110 | $221.05 |
| 87210 | <1% | 291 | $213.58 | |
| 86803 | <1% | 18 | $210.27 | |
| 96368 | <1% | 13 | $200.50 | |
| 85652 | <1% | 1,708 | $187.52 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 2,100 | $177.37 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,733 | $174.15 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,545 | $143.53 |
| 90686 | <1% | 17 | $133.46 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 648 | $130.44 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,054 | $120.32 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,013 | $103.46 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 4,187 | $90.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,108 | $88.83 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 1,733 | $86.94 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 729 | $83.29 |
| C1769 | Guide wire | <1% | 1,751 | $80.84 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 17 | $73.24 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,182 | $72.12 |
| 87205 | <1% | 240 | $57.10 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,205 | $55.50 |
| J1815 | Injection, insulin, per 5 units | <1% | 563 | $53.93 |
| 87807 | <1% | 214 | $51.28 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 1,954 | $48.29 |
| C1758 | Catheter, ureteral | <1% | 97 | $47.96 |
| 87070 | <1% | 191 | $46.79 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 2,576 | $42.39 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 547 | $39.74 |
| 87088 | <1% | 133 | $32.27 | |
| 86592 | <1% | 15 | $26.52 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 325 | $23.11 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 332 | $22.34 |
| S0028 | Injection, famotidine, 20 mg | <1% | 2,077 | $21.40 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 478 | $20.34 |
| A4649 | Surgical supply; miscellaneous | <1% | 495 | $20.33 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 99 | $18.71 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 15 | $16.51 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 481 | $16.01 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 197 | $14.10 |
| 84156 | <1% | 46 | $12.23 | |
| 84100 | <1% | 33 | $8.56 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 82 | $7.42 |
| 82550 | <1% | 127 | $6.63 | |
| 82570 | <1% | 49 | $6.13 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 106 | $4.94 |
| 87015 | <1% | 47 | $4.52 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 15 | $2.96 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 35 | $0.92 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 13 | $0.73 |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 219 | $0.48 |
| J3535 | Drug administered through a metered dose inhaler | 0% | 531 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 553 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 1,776 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 231 | $0.00 |
| A9270 | Non-covered item or service | 0% | 475 | $0.00 |
| 88341 | 0% | 74 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 56 | $0.00 |
| 94644 | 0% | 31 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 60 | $0.00 |
| 80050 | General health panel | 0% | 12 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 154 | $0.00 |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 48 | $0.00 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 26 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 97 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 704 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 190 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 12 | $0.00 |
| 80076 | 0% | 16 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 68 | $0.00 |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml | 0% | 259 | $0.00 |
| 84145 | 0% | 13 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 110 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 122 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 40 | $0.00 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | 0% | 12 | $0.00 |
| 82140 | 0% | 15 | $0.00 | |
| 82365 | 0% | 14 | $0.00 | |
| 93356 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRISETTI, NICOLE (DIRECTOR OF OPERATIONAL SUPPORT)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.